id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-D-0207-0001,FDA,FDA-2026-D-0207,"E22 General Considerations for Patient Preference Studies; International Council for Harmonisation; Draft
Guidance for Industry; Availability",Notice,Notice of Availability,2026-02-06T05:00:00Z,2026,2,2026-02-06T05:00:00Z,,2026-02-06T19:33:49Z,2026-02324,0,0,09000064b9195d41
FDA-2026-D-0207-0002,FDA,FDA-2026-D-0207,E22 General Considerations for Patient Preference Studies; Draft Guidance for Industry,Other,Guidance,2026-02-06T05:00:00Z,2026,2,2026-02-06T05:00:00Z,2026-04-08T03:59:59Z,2026-02-14T13:19:49Z,,1,0,09000064b9193360